Brightree to Sell to ResMed for $800 Million

Cooley is advising Brightree on its $800 million sale to ResMed, a tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care. Subject to customary closing conditions, the transaction is anticipated to close by the end of June.

"The Brightree team is very excited to join forces with ResMed to help post-acute care providers navigate the inherent complexities of the healthcare system and ensure that patients get the care they need," said Dave Cormack, president and CEO of Brightree.

Brightree, which is majority-owned by global investment firm Battery Ventures, offers cloud-based software that helps customers improve clinical and business performance in the post-acute care industries of home/durable medical equipment, home health, and hospice – all areas with high prevalence of sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.